Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.
Full Answer
Why did Bausch Health spin off its eye health business?
Through the spinoff of our eye health business, Bausch Health (“the Company”) aims to unlock value across its two attractive businesses as soon as possible while creating two highly attractive, but dissimilar businesses:
Who is Bausch + Lomb?
Bausch + Lomb – A fully integrated, pure play eye health company built on the iconic Bausch + Lomb brand and long history of innovation; and Bausch Pharma – A diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceutical
Why is Bausch Health (BHC) shares surging?
Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Specifically, the drugmaker's shares were up by a noteworthy 15.9% as of 10:56 a.m. ET Friday.
What kind of company is Bausch Pharma?
Bausch Pharma – A diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceutical Why has Bausch Health decided to spin off its eye health business?
Why is Bausch stock dropping?
Bausch Health stock declined Tuesday after the personal-care products maker reported first-quarter revenue that missed analysts' expectations and sales guidance for 2022 that also was below expectations.
Is Bausch health a good buy?
Bausch Health Companies's analyst rating consensus is a 'Moderate Buy.
What happened to Bausch?
Bausch Health Crashes On Unexpected Loss As Bausch & Lomb Starts Trading. Bausch Health Companies (BHC) reported an unexpected first-quarter loss on Tuesday and BHC stock crashed. During the March quarter, the pharma company lost 43 cents per share on $1.92 billion in sales.
What happened to Bausch & Lomb?
Bausch + Lomb was a public company listed on the NYSE, until it was acquired by private equity firm Warburg Pincus in 2007. In May 2013, it was announced that Canadian-based Valeant Pharmaceuticals would acquire Bausch + Lomb from Warburg Pincus for $8.57 billion in cash.
Is Bausch a good stock?
The financial health and growth prospects of BHC, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Is Bausch and Lomb a good investment?
However, despite supply chain disruptions and increased costs associated with “new normal” dynamics, Bausch + Lomb managed to post positive net income for the first three quarters of 2020 and 2021. Beyond its highly profitable business, the eyecare specialist also features strong cash flow.
Did Bausch and Lomb change name?
Valeant Pharmaceuticals International has completed the change of its company name to Bausch Health Companies, as previously announced in May 2018. The new name is taken from its subsidiary, Bausch + Lomb, an eye-care company, which Valeant acquired in 2013.
Who owns Bausch and Lomb?
Bausch HealthBausch + Lomb / Parent organizationBausch Health Companies Inc. is a Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Wikipedia
What did Valeant do wrong?
Bausch Health, the Canada-based drugmaker formerly known as Valeant Pharmaceuticals, agreed to pay $45 million to settle U.S. charges that it misled investors by improperly accounting for revenue channeled through a mail-order pharmacy it helped to set up.
Where are Bausch and Lomb lenses made?
"Bausch + Lomb is one of the world's most respected eye health brands, due in large part to the high-quality contact lenses manufactured at the Rochester and Waterford sites.
Where is biotrue manufactured?
In total, 21 countries, including the United States , currently offer all three modalities of Biotrue® ONEday contact lenses, which are manufactured and distributed globally from the company's facility in Waterford, Ireland .
Does Bausch and Lomb still make binoculars?
Bausch and Lomb then sold their binoculars company to Bushnell, who manufactured binoculars for many years under the Bausch & Lomb brand name. Even after becoming an independent company in the early 1990's they continued to do so. Now all Bausch & Lomb Binoculars carry the Bushnell brand name.
Bausch's Q3 Earnings Beat Estimates, Revenues Miss
The company’s third-quarter adjusted earnings per share of $1.14 beat the Zacks Consensus Estimate of $1.07 but decreased from $1.31 reported in the year-ago quarter.
Quarter in Detail
Revenues from the Bausch + Lomb segment were $949 million, up 4% year over year.
Bausch's Q4 Earnings and Revenues Surpass Estimates
The company’s adjusted earnings per share of $1.33 easily beat the Zacks Consensus Estimate of $1.11 and increased from $1.15 reported in the year-ago quarter.
Quarter in Detail
Revenues in the Bausch + Lomb/International segment (comprised 56% of the total revenues) were $1.24 billion, flat year over year. Excluding the impact of discontinuations and divestitures, segment sales were flat organically due to the impacts of the COVID-19 pandemic.
